Revolutionizing the treatment paradigm for depression, anxiety, drug addiction, and other debilitating mental illnesses

Our Story

We’re in a global mental health crisis, and available psychiatric medicines fail to address the pressing unmet needs in patients.

Compounded by decades of stagnation, there is a dire need for new treatment options for those suffering from mental illness.

Our mission is to develop novel compounds that capture the therapeutic benefits of psychedelics to fundamentally reshape the treatment of mental illness.

Gilgamesh's AI-powered behavioral and imaging driven platform is accelerating and optimizing the development of our new chemical entities (NCEs) which offer improved safety, tolerability, duration, and efficacy.

We are a team of passionate neuroscience experts with decades of experience within large biopharma (Pfizer, Merck, Regeneron, Biogen, Lilly), exited startups (Perception Neuroscience, Kures, Springworks Therapeutics, Biohaven) and academia (Columbia University, Harvard University, NYU, Yale, UCSD).

Proprietary Scientific Platform

Gilgamesh's discovery platform provides a state-of-the-art neurocircuitry-focused translational approach to novel drug candidate optimization and selection.

The platform aims to identify and classify novel psychoactive drugs by utilizing complex behavioral assessment, advanced electrophysiology and molecular measures of neuroplasticity.

This cutting edge approach incorporates machine learning algorithms to systematically characterize the multidimensional bioactivity of known and novel psychoactive molecules to improve clinical translation.


AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder

Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Why We Invested in Gilgamesh (Again)

JOB Openings

Chief Development and Strategy Officer

AD/Director CMC and Drug Substance

Principal Scientist/Senior Principal Scientist, Discovery Chemistry

Financial Controller

Manager/Senior Manager, Toxicology and ADME

Manager/Sr. Manager Regulatory Operations and QA/QC

Clinical Statistician
Gilgamesh is funded by some of the world’s most notable investors, including Y Combinator and Prime Movers Lab.
YCombinator LogoPrime Movers Lab LogoGRON Ventures LogoPalo Santo LogoRoute 66 VenturesNoetic
Learn more about partnerships, investment, and career opportunities
Contact Us
Gilgamesh Pharmaceuticals
113 University Place, Suite 1019, NY, NY 10003